Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned.
about
Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation.Pharmacological inhibitors of TRPV4 channels reduce cytokine production, restore endothelial function and increase survival in septic miceRegulation of tumour necrosis factor signalling: live or let dieAn Agent-Based Model of a Hepatic Inflammatory Response to Salmonella: A Computational Study under a Large Set of Experimental DataAlarmins: awaiting a clinical responseNew and emerging therapies for sepsis.ANP attenuates inflammatory signaling and Rho pathway of lung endothelial permeability induced by LPS and TNFalpha.Toxic shock syndrome toxin-1-mediated toxicity inhibited by neutralizing antibodies late in the course of continual in vivo and in vitro exposure.Sepsis induced by cecal ligation and puncture.Prophylactic uses of integrin CD18-betaA peptide in a murine polymicrobial peritonitis model.The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophagesLong-term administration of the TNF blocking drug Remicade (cV1q) to mdx mice reduces skeletal and cardiac muscle fibrosis, but negatively impacts cardiac functionToll-like receptor 2 deficiency results in impaired antibody responses and septic shock during Borrelia hermsii infection.Inhibiting TNF-α signaling does not attenuate induction of endotoxin toleranceThe effect of progesterone on systemic inflammation and oxidative stress in the rat model of sepsis.Antitumor necrosis factor therapy is associated with improved survival in clinical sepsis trials: a meta-analysis.ARF6 inhibition stabilizes the vasculature and enhances survival during endotoxic shock.Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with speciaSepsis: a frequent, life-threatening syndrome.Role of tumor necrosis factor-α in the human systemic endotoxin-induced transcriptome.Effective immunomodulatory treatment of Escherichia coli experimental sepsis with thalidomide.The enigma of sepsis.Inhibition of c-Jun-N-terminal kinase increases cardiac peroxisome proliferator-activated receptor alpha expression and fatty acid oxidation and prevents lipopolysaccharide-induced heart dysfunction.Selective improvement of tumor necrosis factor capture in a cytokine hemoadsorption device using immobilized anti-tumor necrosis factor.Microbial superantigens as virulence factors and ways to counteract their actions.Kallistatin treatment attenuates lethality and organ injury in mouse models of established sepsisHematopoietic stem-progenitor cells restore immunoreactivity and improve survival in late sepsisMonocyte Tumor Necrosis Factor-α-Converting Enzyme Catalytic Activity and Substrate Shedding in Sepsis and Noninfectious Systemic Inflammation.Pathophysiology of sepsis-related cardiac dysfunction: driven by inflammation, energy mismanagement, or both?Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study.Association between tumor necrosis factor-alpha G-308A polymorphism and dental peri-implant disease risk: A meta-analysis.Equine endotoxaemia--a state-of-the-art review of therapy.What is new in cytokine research related to trauma/critical care.Fingerprinting of the TLR4-induced acute inflammatory response.Tumour necrosis factor: implications for surgical patients.Inhalation injury severity and systemic immune perturbations in burned adultsTargeting TNF-alpha receptors for neurotherapeuticsAdvances in understanding sepsisProtective effects of Sparstolonin B, a selective TLR2 and TLR4 antagonist, on mouse endotoxin shockFractional excretion of tumor necrosis factor-alpha in women with severe preeclampsia
P2860
Q25255548-2496C12C-22F0-49A7-AD0B-149B3AEB203FQ27345533-3C50852C-E6C2-4FD8-B447-F156351D1603Q28262381-908A15B3-399B-41F9-B6A1-5802FDCA7E5AQ30000073-F8F642DF-03C1-4DE5-AAE5-92C92C1DAA6BQ30523797-F8F60B09-49DA-4ADF-9BA1-F720F5125FD0Q33183531-68CD51D3-0D4D-4A13-8896-69431F7D1B42Q33618498-BECC7196-FD47-466A-A023-A4E37B87F9ABQ33813616-7B7D497C-788A-41FA-B24E-2D653EA226FCQ33844878-9DB64286-3367-424D-B228-C97146D8132AQ33894207-7A233CEA-D4B1-4179-9CB1-9A70595D841AQ33895703-95F455B6-6D2E-4436-9DAF-554C61DAD542Q34005353-C619B65D-C44A-4F48-83E9-46F03C996DB1Q34290670-FF60B648-1305-46A3-8A6E-D2800C2BED51Q34655635-1A3C7462-C4B1-4624-B739-1E14E77A6220Q34684628-4635C7F0-94F0-4AD1-BD91-645769CD3211Q34866465-CE9410D8-3C8F-46C2-B4E9-A2A2665F8602Q34917691-D85A9473-C7D5-40CA-BDA3-7B396959AC7EQ35018415-ACC9A376-3F00-4261-A391-4FB73463F9A2Q35030565-4BBF6828-2B36-430D-970A-4534B2A69FB1Q35043680-ED72D2FB-CE2C-4660-B660-15811D07A44EQ35166127-3AA12442-8341-4B22-9F7B-54FEA902E978Q35202458-2BCC357C-4571-48D9-8BF6-AD3D7B06858FQ35378402-55D843D3-0C14-4695-AAC7-839ABFB0BCE2Q35565550-CDCBA2B6-067A-4224-9A76-7EE01D579234Q35585080-9A7D5B27-E0BB-4F33-9147-ABFF794928E5Q35654838-88CEB338-9292-48FC-96EA-C9B184D57C19Q35689431-CC163A1C-64F1-4606-9301-3898696CE3ADQ35743018-3795A927-3B5B-41A7-8E49-58CF1A1628D4Q35761448-CD4323F8-37CB-4BC7-8104-6B548820DE61Q35830749-202B1FD3-B765-4E12-A652-23CB370A5FBEQ36119919-623BD899-3A80-4531-BDA5-6F8039BE9455Q36171180-86842D3D-24A9-4356-9BD9-2F2CEFAF65F7Q36421394-1499BF9E-D56C-4B5F-AADE-CDAA6A680E3AQ36456656-EBED8993-29AF-438A-961D-DAB33ED33020Q36630054-486A4ADD-BE50-4F77-BC89-4A47C19964FCQ36632003-87548EF2-A412-4B39-8CDC-F0E54EBE82F0Q36953319-124748CF-BA61-44AF-8685-A6F3A9A90C83Q37090618-5E2E0D25-C316-4DFB-BBDD-647C3FE419ADQ37108130-1CD3F337-1C68-4916-A6FF-D50FED68ADFBQ37163195-EC5C028E-89D5-41DF-9B58-B8996BF0DF09
P2860
Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Anti-tumor necrosis factor the ...... al trials and lessons learned.
@ast
Anti-tumor necrosis factor the ...... al trials and lessons learned.
@en
Anti-tumor necrosis factor the ...... al trials and lessons learned.
@nl
type
label
Anti-tumor necrosis factor the ...... al trials and lessons learned.
@ast
Anti-tumor necrosis factor the ...... al trials and lessons learned.
@en
Anti-tumor necrosis factor the ...... al trials and lessons learned.
@nl
prefLabel
Anti-tumor necrosis factor the ...... al trials and lessons learned.
@ast
Anti-tumor necrosis factor the ...... al trials and lessons learned.
@en
Anti-tumor necrosis factor the ...... al trials and lessons learned.
@nl
P1476
Anti-tumor necrosis factor the ...... al trials and lessons learned.
@en
P2093
P304
P356
10.1097/00003246-200107001-00037
P407
P433
P577
2001-07-01T00:00:00Z